Shares of Juno Therapeutics jump after FDA removes clinical hold on cancer drug trial

News Hour:

Juno Therapeutics Inc  said U.S. health regulators have removed a clinical hold on its cancer drug trial that was put in place last week following the death of three patients, sending its shares up about 28 percent in extended trading.

Last week, the U.S. Food and Drug Administration halted the mid-stage trial of the company’s genetically engineered cancer drug after three leukemia patients died from side effects, reports Reuters.

Juno said the deaths occurred after the chemotherapy agent fludarabine was added to the trial program. Under the new protocol, the trial will continue enrollment using the original drug regimen, without fludarabine.

The drug, JCAR015, is an experimental therapy requiring a complicated process of extracting immune system T cells from an individual patient, altering their DNA to sharpen their ability to spot and kill cancer cells, and infusing them back into the same patient.

Rafiuzzaman Sifat

Md. Rafiuzzaman Sifat, a CSE graduate turned into journalist, works at News Hour as a staff reporter. He has many years of experience in featured writing in different Bangladeshi newspapers. He is an active blogger, story writer and social network activist. He published a book named 'Se Amar Gopon' inEkushe boi mela Dhaka 2016. Sifat got a BSc. from Ahsanullah University of Science & Technology, Bangladesh. He also works as an Engineer at Bangla Trac Communications Ltd. As an avid traveler and a gourmet food aficionado, he is active in publishing restaurant reviews and cutting-edge articles about culinary culture.
No Comments

Join Epidemiology Congress 2019

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Advertisement

News of the Month

Scroll Up
%d bloggers like this: